論　文　（英　文）

Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis.
Fujimori T, Shibayama Y, Kanda T, Suzuki K, Ogawa D, Ishikawa R, Kadota K, Matsunaga T, Tamiya T, Nishiyama A, Miyake K.
Sci Rep. 16;13(1):808. 2023

Antiproliferative effects of D-allose associated with reduced cell division frequency in glioblastoma.
Suzuki K, Ogawa D, Kanda T, Fujimori T, Shibayama Y, Rahman A, Ye J, Ohsaki H, Akimitsu K, Izumori K, Tamiya T, Nishiyama A, Miyake K.
Sci Rep. 9;13(1):19515. 2023

A prospective study of intensity-modulated radiation therapy using a standard radiation dose for high-grade glioma.
Takahashi S, Miyake K, Ogawa D, Anada M, Kinoshita T, Nishide T, Shibata T.
Cancer Diagn Progn. 3;3(4):491-497. 2023

^{18}F-Fluoromisonidazole-positron emission tomography and immunohistochemistry verified tumor oxygenation, stemness, and immunosupportive microenvironment after preoperative neoadjuvant bevacizumab for newly diagnosed glioblastoma.
Suzuki T, Takei J, Fukasawa N, Suzuki K, Ogawa D, Yamamoto Y, Akasaki Y, Murayama Y, Shimoda M, Miyake K, Tanaka T.
World Neurosurg. 175:e1364-e1374. 2023

Current treatment results of intracranial carotid artery dissection causing cerebral ischemia: A Japanese Nationwide Survey.
Shimizu H, Ono T, Abe T, Hokari M, Egashira Y, Kawanishi M, et al.
Neurol Med Chir (Tokyo). 15;63(2):80-89. 2023.

Comparative evaluation of 11C-methionine and 18F-fuorodeoxyglucose positron emission tomography for distinguishing between primary central nervous system lymphoma and isocitrate dehydrogenase-wildtype glioblastoma.

Norikane T, Mitamura K, Yamamoto Y, Manabe Y, Murao M, Okuda H, Hatakeyama T, Miyake K, Nishiyama Y

J Neurooncol. Online ahead of print. 2023